We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ANI Pharmaceuticals Announces an Agreement with Sofgen
News

ANI Pharmaceuticals Announces an Agreement with Sofgen

ANI Pharmaceuticals Announces an Agreement with Sofgen
News

ANI Pharmaceuticals Announces an Agreement with Sofgen

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ANI Pharmaceuticals Announces an Agreement with Sofgen"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ANI Pharmaceuticals has announced that it has signed a binding letter of intent for the development of an oral soft gel prescription product with Sofgen Pharmaceuticals.

The product, indicated for cardiovascular health, will be the subject of an Abbreviated New Drug Application (“ANDA”) filing.

Sofgen will be responsible for the development, manufacturing and regulatory submission of the product and ANI will be responsible for marketing and distribution in the United States.

Arthur S. Przybyl, ANI’s President and CEO stated, “I am pleased to have entered into this collaboration with Sofgen for an oral soft gel drug. In addition to our internal product development efforts, we will continue to pursue opportunities through external partnerships and acquisitions in order to leverage our core capabilities in manufacturing and marketing. We are fortunate to have such a high quality partner in Sofgen.”

Advertisement